With $50 Million in Upfront Money, Takeda and Enterome Double Down on Crohn’s DiseaseAllbiopro2018-10-24T10:29:23+09:0010월 24th, 2018|
Billionaire Activist Has Invested Over $100 Million for Cheaper MedsAllbiopro2018-10-24T10:28:55+09:0010월 24th, 2018|
Billionaire Activist Has Invested Over $100 Million for Cheaper MedsAllbiopro2018-10-24T10:28:29+09:0010월 24th, 2018|
Biogen and UCB’s Lupus Treatment Fails Phase II Clinical TrialAllbiopro2018-10-24T10:28:03+09:0010월 24th, 2018|
With Money and Equity Changing Hands, Innate Pharma and AstraZeneca Move Deeper into an Immuno-oncology PactAllbiopro2018-10-24T10:27:36+09:0010월 24th, 2018|
10 Months After Abandoning Neuroscience R&D, Pfizer Launches CNS Company Cerevel TherapeuticsAllbiopro2018-10-24T10:27:06+09:0010월 24th, 2018|
Bay Area’s Biotech Talent Crisis Puts Job Seekers in the Driver’s SeatAllbiopro2018-10-24T10:26:37+09:0010월 24th, 2018|
Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan’s Ci:zAllbiopro2018-10-24T10:26:09+09:0010월 24th, 2018|
Cool it, analyst urges ‘overly punitive’ BMS investors after rough Opdivo weekAllbiopro2018-10-24T10:25:40+09:0010월 24th, 2018|
Biogen biosimilars and Spinraza fill MS void, but pipeline worries aboundAllbiopro2018-10-24T10:25:12+09:0010월 24th, 2018|
Johnson & Johnson inks last-minute Risperdal deal in boy-with-breasts caseAllbiopro2018-10-24T10:24:43+09:0010월 24th, 2018|
ESMO’s not what it used to be—and that’s a good thing, executives sayAllbiopro2018-10-24T10:24:16+09:0010월 24th, 2018|
Stoke Therapeutics nabs $90M series B for oligonucleotide workAllbiopro2018-10-24T10:23:47+09:0010월 24th, 2018|
AstraZeneca strikes big, multipart immuno-oncology deal with InnateAllbiopro2018-10-24T10:23:19+09:0010월 24th, 2018|
Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCBAllbiopro2018-10-24T10:22:52+09:0010월 24th, 2018|
Pathogens may evade immune response with metal-free enzyme required for DNA replicationAllbiopro2018-10-24T10:21:34+09:0010월 24th, 2018|
